Precision NanoSystems and Arcturus Therapeutics announce partnership for manufacture of nanomedicines

1 minute read
01 January 2015
Client work

On January 9, 2015, Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, announced a partnership for the manufacture of RNA medicines.

Under the terms of the agreement, Precision’s proprietary NanoAssemblr™ platform will be used to manufacture GMP batches to support clinical studies and commercial development for RNA medicines developed using Arcturus’ proprietary LUNAR™ RNA Therapeutics platform.

Paul Armitage of Gowlings advised Precision NanoSystems with respect to the negotiation of this partnership.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences, Tech, Intellectual Property Law

Related Insights & Resources

View all insights Related Insights & Resources
Articles
13 October 2021 Patent applications - Consider requesting examination now to avoid proposed excess claim fees
Articles
08 October 2021 UK Court's 'willingness' decision in Optis v Apple to be appealed
electric charging station On-demand webinar
08 October 2021 Scale-up! Factors to consider when scaling your business in BC's cleantech sector
Download or print PDF